France

On June 2, 2026, the Decision of the National Union of Health Insurance Funds (UNCAM) updating the Nomenclature of Medical Biology Procedures (NABM) was released. The NABM is France’s primary permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance. The update introduces regular reimbursement for four new codes, including two next-generation sequencing (NGS) panels that were previously covered temporarily under the innovative payment scheme (RIHN framework).

In May 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of two new devices. Opinions concerned orthopedics and the peripheral vascular fields.

On May 20, 2026, the French Ministry of Health published the Decree, establishing a phase-out mechanism for older medical telemonitoring activities reimbursed via LATM when a newer, superior solution is registered for the same indication. Older solutions are subject to a 36-month transitional period before the removal, with three successive annual tariff reductions of 10% vs. the tariff of the newly registered solution.

In April 2026, the French Ministry of Health published an update to the 2026 List of Innovative Procedures Outside the Nomenclature (LAHN), which includes innovative IVD tests temporarily funded under the RIHN framework. The update introduced two new “duplicative” codes in the field of cytogenetics that are exempt from the tariff reduction mechanism.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of 14 new devices and for the extension of indications for three devices. Opinions concerned multiple fields, including cardiovascular, diagnostic imaging, ENT, e-health, endocrine, interventional radiology, nephrology, neuromodulation, orthopedics, spine, peripheral vascular, and pulmonology.

On April 16, 2026, the French Ministry of Health announced the inclusion of the first in vitro diagnostic medical device under the reformed RIHN 2.0, designed to support innovative diagnostics through temporary reimbursement while evidence is generated. The selected technology is VisioCyt Bladder, an AI-assisted digital urine cytology, indicated for monitoring recurrence in non-muscle-invasive bladder cancer. This marks a key milestone in the implementation of the updated framework.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the March 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favorable opinion was issued on the add-on reimbursement for three new devices in the gastrointestinal endoscopy, men’s health, and orthopedics fields.

In February 2026, the French Ministry of Health, Family, Autonomy, and People with Disabilities announced three new experiments under Article 51 of the Social Security Financing Act. They relate to nephrology and neuro-orthopedics, and to the provision of care to discharged, dependent, elderly individuals experiencing loss of autonomy or chronic illness.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the February 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favourable opinions were issued on the add-on reimbursement for six new devices and on the extension of indications for two devices, in the cardiovascular, peripheral vascular, and ENT fields.

A new version of the Nomenclature of Medical Biology Procedures (NABM 102), effective from March 3, 2026, was published in France. Changes include the introduction of one new code and the deletion and modification of several codes.

On February 7, 2026, the Ministry of Health, Family, Autonomy and People with Disability released an update of the 2014 regulations on conditions of performing IVD tests outside the medical biology laboratory. The new regulation expands the list of locations eligible for point-of-care testing (POCT) and provides an explicit list of tests that can be performed as POCT, and links them to eligible locations. It also introduces a quality assurance framework, accreditation requirements, and mandates that comprehensive conventions be concluded between the remote sites providing POCT and the responsible laboratories.

In early February 2026, the French National Authority for Health (HAS) opened the call for applications for the evaluation of medical procedures and in-vitro diagnostic (IVD) tests to be included in its 2027 working program. The deadline for submission is May 4, 2026.